Skip to main content
Clinical Trials/NCT04576897
NCT04576897
Completed
Not Applicable

Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Liver Stiffness Measurement Using Liver Incytes

Indiana University1 site in 1 country70 target enrollmentFebruary 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Portal Hypertension
Sponsor
Indiana University
Enrollment
70
Locations
1
Primary Endpoint
Platelet Count for Participants With Compensated Advanced Chronic Liver Disease
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a cross sectional study that evaluates the relationship between LSM (liver stiffness measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver disease) and manifestations of portal hypertension.

Detailed Description

The purpose of this study is to assess the severity of portal hypertension in people with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplant by measuring liver stiffness with the Liver Incytes device (Velacur) and comparing the performance of LSM (liver stiffness measurement) via Velcaur and transient elastography via FibroScan to esophageal varices.

Registry
clinicaltrials.gov
Start Date
February 1, 2021
End Date
April 19, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Samer Gawrieh

Professor of Clinical Medicine

Indiana University

Eligibility Criteria

Inclusion Criteria

  • Adults aged 18 years or older
  • Ability to provide informed consent
  • Planned standard of care upper endoscopy to screen for varices
  • Planned standard of care transjugular liver biopsy with portal pressure measurement

Exclusion Criteria

  • Inability or refusal to provide informed consent
  • Fasting for less than three hours prior to the scan
  • Subject is a pregnant or lactating female
  • Subject with current, significant alcohol consumption
  • Patients with a pacemaker or defibrillator
  • Acute hepatitis defined as AST/ALT \> 500 U/L
  • post liver transplantation

Outcomes

Primary Outcomes

Platelet Count for Participants With Compensated Advanced Chronic Liver Disease

Time Frame: one day

Comparing the platelet count in the same patient population to determine Velacur's accuracy in correlating with compensated advanced chronic liver disease (cACLD) for participants with and without esophageal varices

Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)

Time Frame: one day

Comparing the performance of Velacur by Sonic Incytes to transient elastography via FibroScan® in the same patient population to determine if either test is more accurate in correlating with compensated advanced chronic liver disease (cACLD) for participants with and without esophageal varices.

Study Sites (1)

Loading locations...

Similar Trials